US2016331712A1PendingUtilityA1

Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system

37
Assignee: GEORGIOU TASSOSPriority: Dec 19, 2013Filed: Dec 19, 2013Published: Nov 17, 2016
Est. expiryDec 19, 2033(~7.4 yrs left)· nominal 20-yr term from priority
Inventors:Tassos Georgiou
A61P 43/00A61P 9/10A61P 27/06A61P 25/02A61P 27/02A61P 25/00A61K 2300/00A23V 2200/08A23V 2002/00A61K 31/202A23V 2250/187A23L 33/12A23V 2250/1868A23V 2200/322
37
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions comprising omega 3 fatty acids for use in the treatment, amelioration or prevention of various conditions, disorders, and diseases which involve damage to the nervous system, as the peripheral nervous system neuropathy and glaucoma.

Claims

exact text as granted — not AI-modified
1 - 20 . (canceled) 
     
     
         21 . A composition for treating diseases involving damage to the nervous system comprising between 3 g and 15 g of eicosapentaenoic acid and docosahexaenoic acid, in a mass ratio EPA:DHA from 1:1 to 5:1, for use in the treatment, amelioration or prevention of optic nerve damage. 
     
     
         22 . The composition according to  claim 21 , wherein the optic nerve damage is selected from the group including optic nerve damage due to glaucoma, ischemic optic neuropathy (ION), and optic neuritis. 
     
     
         23 . The composition according to  claim 22 , for use in the treatment, amelioration, or prevention of optic neuritis. 
     
     
         24 . The composition according to  claim 21 , for use in the treatment, amelioration, or prevention of glaucoma. 
     
     
         25 . The composition according to  claim 21 , wherein the amount of eicosapentaenoic acid and docosahexaenoic acid administered comprises between 3 g to 15 g per day. 
     
     
         26 . The composition according to  claim 25 , wherein the amount of eicosapentaenoic acid and docosahexaenoic acid administered is greater than 7.5 g per day. 
     
     
         27 . The composition according to  claim 26 , wherein the amount of eicosapentaenoic acid and docosahexaenoic acid administered is between 7.5 g and 10 g per day. 
     
     
         28 . The composition according to  claim 21 , wherein the composition is a pharmaceutical composition. 
     
     
         29 . The composition according to  claim 21 , wherein the composition is a food composition. 
     
     
         30 . The composition according to  claim 21 , wherein the arachidonic acid/eicosapentaenoic acid mass ratio in the blood is in the range of 0.8 to 3, preferably from 1 to 1.5.

Join the waitlist — get patent alerts

Track US2016331712A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.